Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo offers hope for Hard-to-Treat blood cancer

NCT ID NCT06712121

First seen Feb 02, 2026 · Last updated May 20, 2026 · Updated 14 times

Summary

This study tests whether a combination of two drugs, venetoclax and decitabine, can help adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatment. About 28 participants aged 19 to 79 will receive this modified chemotherapy regimen. The goal is to see if the treatment can achieve complete remission or significant blood cell recovery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Seoul National University Bundang Hospital

    NOT_YET_RECRUITING

    Seongnam-si, 13620, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Seoul National University Hospital

    NOT_YET_RECRUITING

    Seoul, 03080, South Korea

  • Seoul National University Hospital

    RECRUITING

    Seoul, 03080, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.